Učitavanje...
A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models
Previous studies show that cyclophilins contribute to many pathologic processes, and cyclophilin inhibitors demonstrate therapeutic activities in many experimental models. However, no drug with cyclophilin inhibition as the primary mode of action has advanced completely through clinical development...
Spremljeno u:
| Izdano u: | J Pharmacol Exp Ther |
|---|---|
| Glavni autori: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
The American Society for Pharmacology and Experimental Therapeutics
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6815936/ https://ncbi.nlm.nih.gov/pubmed/31406003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.119.261099 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|